Prospective validation of a 21-gene expression assay in breast cancer

New England Journal of Medicine

Volumn 373, Issue 21, 2015, Pages 2005-2014

  Sparano, J A ^a   Gray, R J ^b   Makower, D F ^d   Pritchard, K I ^c   Albain, K S ^e   Hayes, D F ^g   Geyer, C E ^h   Dees, E C ⁱ   Perez, E A ^m   Olson, J A ^j,n   Zujewski, J A ^k,o   Lively, T ^o   Badve, S S ^p   Saphner, T J ^r   Wagner, L I ^f   Whelan, T J ^c   Ellis, M J ^t,v   Paik, S ^w,y   Wood, W C ^z   Ravdin, P ^u   Keane, M M ^aa   Gomez Moreno, H L ^ab   Reddy, P S ^ac   Goggins, T F ^s   Mayer, I A ^ad   Brufsky, A M ^x   Toppmeyer, D L ^ae   Kaklamani, V G ^f   Atkins, J N ^l   Berenberg, J L ^af   Sledge, G W ^q,ag   more..

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Canada   (Canada)

^d JURAVINSKI CANCER CENTRE   (Canada)

^e LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

^k WAKE FOREST SCHOOL OF MEDICINE   (United States)

^l Southeast Clinical Oncology Research Consortium NCORP   (United States)

^m MAYO CLINIC   (United States)

ⁿ UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^o NATIONAL INSTITUTES OF HEALTH   (United States)

^p INDIANA UNIVERSITY   (United States)

^q INDIANA UNIVERSITY   (United States)

^r Aurora Healthcare   (United States)

^s Fox Valley Hematology Oncology Associates   (United States)

^t BAYLOR COLLEGE OF MEDICINE   (United States)

^u UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^v WASHINGTON UNIVERSITY   (United States)

^w ALLEGHENY GENERAL HOSPITAL   (United States)

^x UNIVERSITY OF PITTSBURGH   (United States)

^y Yonsei University College of Medicine   (South Korea)

^z EMORY UNIVERSITY   (United States)

^aa All Ireland Cooperative Oncology Research Group   (Ireland)

^ab INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^ac Cancer Center of Kansas   (United States)

^ad VANDERBILT UNIVERSITY   (United States)

^ae RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^af UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^ag STANFORD UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RECURRENCE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION ASSAY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL RATE; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; EPIDEMIOLOGY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; KAPLAN MEIER METHOD; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVENTION AND CONTROL; SURVIVAL ANALYSIS; TUMOR RECURRENCE; VALIDATION STUDY;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 84947730258     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1510764     Document Type: Article

References (37)

1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19:1893-907.
2. Hayes D, Padnos SB. Predictive and prognostic markers in cancer. Clin Adv Hematol Oncol 2011;9:130-2.
3. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immuno-histochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-95.
4. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997-4013.
5. Mansour EG, Gray R, Shatila AH, et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: an inter-group study. N Engl J Med 1989; 320: 485-90.
6. Mansour EG, Gray R, Shatila AH, et al. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis-an intergroup study. J Clin Oncol 1998; 16: 3486-92.
7. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89: 1673-82.
8. Peto R, Davies C, Godwin J, et al. Comparisons between different polyche-motherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100, 000 women in 123 randomised trials. Lancet 2012;379:432-44.
9. Abrams JS. Adjuvant therapy for breast cancer-results from the USA consensus conference. Breast Cancer 2001; 8: 298-304.
10. Munoz D, Near AM, van Ravesteyn NT, et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst 2014;106(11):pii.
11. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
12. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
13. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771-84.
14. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008;26:721-8.
15. Paik S, Shak S, Tang G, et al. A multi-gene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26.
16. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34.
17. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmeno-pausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11: 55-65.
18. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-52.
19. Hayes DF. Biomarker validation and testing. Mol Oncol 2015; 9: 960-6.
20. Duffy MJ, Sturgeon CM, Sölétormos G, et al. Validation of new cancer biomark-ers: a position statement from the European Group on Tumor Markers. Clin Chem 2015;61:809-20.
21. Carlson RW, Brown E, Burstein HJ, et al. NCCN Task Force report: adjuvant therapy for breast cancer. J Natl Compr Canc Netw 2006;4:Suppl 1: S1-S26.
22. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
23. Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007; 25: 2127-32.
24. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-312.
25. Sparano JA, Zhao F, Martino S, et al. Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer. J Clin Oncol 2015;33:2353-60.
26. Sparano JA, Fazzari M, Kenny PA. Clinical application of gene expression profiling in breast cancer. Surg Oncol Clin N Am 2010; 19: 581-606.
27. Sgroi DC, Sestak I, Cuzick J, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 2013;14:1067-76.
28. Sestak I, Cuzick J. Markers for the identification of late breast cancer recurrence. Breast Cancer Res 2015; 17: 10.
29. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in post-menopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-802.
30. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805-16.
31. Drukker CA, Bueno-de-Mesquita JM, Retel VP, et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 2013;133:929-36.
32. Bueno-de-Mesquita JM, van Harten WH, Retel VP, et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 2007; 8: 1079-87.
33. Cardoso F, Piccart-Gebhart M, Van't Veer L, Rutgers E. The MINDACT trial: the first prospective clinical validation of a genomic tool. Mol Oncol 2007; 1: 246-51.
34. Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinico-pathologic features. J Clin Oncol 2008; 26: 4063-71.
35. Tang G, Shak S, Paik S, et al. Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 2011; 127: 133-42.
36. Wong WB, Ramsey SD, Barlow WE, Garrison LP Jr, Veenstra DL. The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). Con-temp Clin Trials 2012; 33: 1117-23.
37. Bartlett J, Canney P, Campbell A, et al. Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial. Clin Oncol (R Coll Radiol) 2013; 25: 109-16.